Beckley Psytech

Beckley Psytech is a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for unmet needs in neuropsychiatry. Our lead compound, BPL-003 (5-MeO-DMT), is being studied for treatment-resistant depression.

We combine decades of psychedelic research from the Beckley Foundation with modern pharmaceutical development to bring breakthrough treatments to patients worldwide.